Personal Genome Diagnostics Collaborates on Study Uncovering New Actionable Mutations and Prognostic Predictors in Pancreatic Cancer.
Study in Nature Communications identifies new predictors of patient outcome and suggests targeted therapy approaches may benefit more patients than previously thought.